Alumis Inc. Share Price & Technical Analysis
ALMS · $22.48 (+2.09%)
Healthcare / Biotechnology
$22.48
+2.09%
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of…
Price chart
Seasonality
May has 0 positive and 2 negative years (last 3 years shown)
-11% return in May, -15% avg return in past 3 year May month.
146% return in 2026, 13% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 150% | 21% | -24% | 10% | -11% | – | – | – | – | – | – | – | 146% |
| 25 | -5% | -36% | 30% | -34% | -15% | -17% | 37% | 12% | -13% | 20% | 64% | 31% | 73% |
| 24 | – | – | – | – | – | -1% | -4% | 2% | -16% | 5% | -18% | -14% | -48% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Emerging · Neutral
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$2.94B
P/E ratio
—
52W high
$30.60
52W low
$2.76
Volume
58,423
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Alumis Inc. share price today?
- Alumis Inc. (ALMS) last traded around $22.48 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does ALMS have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for ALMS. Download the app for real-time alerts.
- How can I analyze Alumis Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.